We read the letter by Caballero and Clearkinl regarding their use of a single 0.4 ml injection containing 10 mg (25 mg/ml) 5-fluorouracil (5-FU) into the potential space between Tenon's capsule and the conjunctiva.
We read the letter by Caballero and Clearkinl regarding their use of a single 0.4 ml injection containing 10 mg (25 mg/ml) 5-fluorouracil (5-FU) into the potential space between Tenon's capsule and the conjunctiva.
However, we write to urge great caution with the use of antimetabolites injected directly into the filtration bleb when there is a patent sclerostomy, even one covered by a scleral flap. Surgeons with less experience than Drs. Caballero and Clearkin run the risk of injecting concen trated 5-FU directly into the bleb drainage area, which has direct access to the anterior chamber. In addition, if the conjunctiva has been closed (unlike the technique used by Caballero and Clearkin) the pressure in the bleb could, depending on the volume of 5-FU used, rise higher than that in the eye. Also, the intraocular pressure immediately following filtration surgery may be near 0 mmHg and may potentially reach a negative pressure depending on the traction forces on the eye. In this situation, 5-FU or any other antimetabolite may be pushed or sucked into the eye, theoretically achieving a very high concentration in the anterior chamber. In addition to its direct antimetabolic effect, commercially available 5-FU is solubilised using sodium hydroxide, resulting in a solution with an alkaline pH near to 9 which may enter the eye.
We have also heard accounts of other surgeons injecting antimetabolites, including 5-FU and even mitomycin C, directly into the filtration area between Tenon's capsule and the sclera after conventional filtration surgery or laser sclerostomy. This practice considerably increases the chance of concentrated solutions of antimetabolites enter ing the anterior chamber. Derick and coworkers2 have described the catastrophic results when the equivalent of one drop (50 Ill) of mitomycin C (0.5 mg/ml) is injected into the anterior chamber of the eye.
The advantage of injecting antimetabolites into the fil tration area is to achieve maximal concentrations in the desired area with relative sparing of other areas, including the corneal epithelium. This can be achieved much more safely by the intraoperative application of sponges soaked in the antimetabolite at the appropriate concentration, which is then rinsed out before the eye is opened.3 Com parisons of the pharmacokinetic data for the intraoperative technique4 versus injections5,6 suggest that intraoperative Eye (1993) 7,481-482 technique with washout is much safer than injections into the bleb site.
We agree that the peak concentration of 5-FU is in many ways more relevant than the total dose, as suggested by Bale and this is supported by our cell culture studies which have shown that human Tenon's fibroblasts can be growth-arr ested for several weeks by 5-FU or mitomycin C in vivo 8 , 9 and in vitro lo after exposures as short as 5 min utes. As such, the clinical results obtained by Drs. Caball ero and Clearkinl and Ball, II who inject 5-FU directly into the bleb site, should be reproducible by 5-minute expo sures to appropriate concentrations of 5-FU or mitomycin C. 12 On the basis of these results we now use single-dose intraoperative exposures to either 5-FU or mitomycin C at different concentrations which are only occasionally sup plemented with post-operative injections,13-15 depending on the patient risk factor profile and clinical course.
In conclusion, we would like to advise great caution with regard to the practice of injecting concentrated 5-FU directly into the filtration area after glaucoma filtration surgery. Clinicians are advised that they run the risk of injecting concentrated 5-FU directly into the anterior chamber with this technique, with potentially serious complications. Additionally, in the light of present knowl edge, mitomycin C should never be injected into the fil tration bleb area after surgery. Sir, Hulbert and Ve rnon! have performed a valuable service in reminding ophthalmologists who treat diabetic retino pathy of the importance of preserving as much of the visual field as possible. However, I suspect that they may be advocating dangerous undertreatment of patinets with proliferative diabetic retinopathy.
Most authors recognise that 'complete treatment' of proliferative retinopathy by panretinal photocoagulation requires approximately 1800-2000 laser bums of 500 �m size. This was the basis of laser treatment applied in the Diabetic Retinopathy Study2 and forms the guidelines for present-day management of proliferative diabetic retino pathy.3 Patients with aggressive retinopathy may well, of course, require much more laser treatment.
Hulbert and Vernon advocate the use of 200 �m spot size laser bums and comment in their guidelines that 'between 3000 and 3500 carefully applied bums induces regression in all but severe cases'. Using a 200 �m spot size it would require 12 500 laser bums to cover the same area of retina as the' conventional' 2000 bums of spot size 500 �m. They therefore appear to be advocating consider-LETTERS TO THE EDITOR ably less laser treatment than is currently the norm, and I suspect this could well be a dangerous undertreatment. Furthermore, as far as I am aware, this form of treatment has never been tested in controlied studies and as such should, in my opinion, be regarded with caution.
Sir, I am grateful to Mr. Gibson for re-emphasising the import ance of delivering sufficient laser photocoagulation tQ induce neovascular regression in proliferative diabetic ret inopathy. I had hoped that this would be covered by Guide line 5 in our paper.! We are, of course, aware that our suggestions (specifically designed for individuals who require a driving licence) result in a smaller area of retina being photocoagulated. Our experience, as outlined in the tables,! would indicate that, based on the degree of sever ity of retinopathy of patients referred to our clinic, many do not require our 'standard retinal ablation' to induce stability of their disease. Titrating treatment in these patients, provided there are adequate facilities for fol low-up, would not appear to prejudice the end result; thus a decision to deliver 2000 bums at 500 �m spot size in a patient who does not need that volume of photocoag ulation is clearly unjustified. Conversely, patients with rapidly progressive, aggressive retinopathy (which would fall into the severe category) must be treated with more extensive photo-ablation.
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